Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?
Docetaxel is currently indicated for androgen-independent, metastatic prostate cancer; there is also evidence demonstrating the role of CYP1B1 in modulating the activity of the drug. We present the case of a man with residual disease after radical prostatectomy treated successfully with docetaxel chemotherapy. After only two cycles of therapy, a complete remission was obtained and then consolidated with additional cycles of docetaxel and radiotherapy. Prospective genetic analysis had shown that the patient had a favourable CYP1B1 genotype. He has been disease free since August 2006. Prospective trials investigating this strategy are warranted.
Brandi
Giovanni
G
Institute of Haematology and Medical Oncology L. e A. Seràgnoli, Policlinico Sant'Orsola Malpighi, University of Bologna, Via Massarenti 9, Bologna, Italy. giovanni.brandi@unibo.it
de Rosa
Francesco
F
Danesi
Romano
R
Montini
Gian Carlo
GC
Biasco
Guido
G
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D065633:Cytochrome P-450 CYP1B1; D018450:Disease Progression; D000077143:Docetaxel; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D012074:Remission Induction; D043823:Taxoids / Q000627:therapeutic use*; D013997:Time Factors
D000970:Antineoplastic Agents; D007527:Isoenzymes; D043823:Taxoids; D000077143:Docetaxel; D001189:Aryl Hydrocarbon Hydroxylases; C585496:CYP1B1 protein, human; D065633:Cytochrome P-450 CYP1B1